Literature DB >> 20218013

Pharmacokinetics of methotrexate in solid tumors.

R K Jain1, J Wei, P M Gullino.   

Abstract

The transport of methotrexate (MTX) into Walker 256 carcinoma (W256) and hepatoma 5123 (H5123) transplanted in rats was investigated after a pulse injection and continuous infusion of the drug. A mathematical model was developed which adequately described the distribution and transport of MTX in both solid tumors. In H5123 the uptake was limited by the amount of drug carried by plasma (flow-limited transport), but in W256 MTX uptake was limited by the rate at which the drug crossed the tissue barriers (tissue-limited transport). Relative uptake by the solid tumors was almost eightfold more efficient with low than with high doses. MTX concentration in tumor interstitial fluid equilibrated with that of plasma in about 50 hr using a micropore chamber with a diffusion coefficient of 0.5 microm/min as sampling device. MTX concentration was higher in resistant than in responsive tumors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 20218013     DOI: 10.1007/bf01059737

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  11 in total

1.  Cage for continuous intravascular infusion of isotopes and drugs in small animals.

Authors:  F H Grantham; D M Hill; J Rowland; P M Gullino
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

Review 2.  THE BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ACTION AND EFFECTS OF THE FOLIC ACID ANTAGONISTS.

Authors:  W C WERKHEISER
Journal:  Cancer Res       Date:  1963-09       Impact factor: 12.701

3.  Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells.

Authors:  G A FISCHER
Journal:  Biochem Pharmacol       Date:  1961-07       Impact factor: 5.858

4.  Some characteristics of transplantable rat hepatoma No. 5123 induced by ingestion of N-(2-fluorenyl) phthalamic acid.

Authors:  H P MORRIS; H SIDRANSKY; B P WAGNER; H M DYER
Journal:  Cancer Res       Date:  1960-09       Impact factor: 12.701

5.  Pharmacokinetic considerations on resistance to anticancer drugs.

Authors:  R L Dedrick; D S Zaharko; R A Bender; W A Bleyer; R J Lutz
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

6.  Transport and binding of methotrexate in vivo.

Authors:  R L Dedrick; D S Zaharko; R J Lutz
Journal:  J Pharm Sci       Date:  1973-06       Impact factor: 3.534

7.  Antibiotics alter methotrexate metabolism and excretion.

Authors:  D S Zaharko; H Bruckner; V T Oliverio
Journal:  Science       Date:  1969-11-14       Impact factor: 47.728

Review 8.  The internal milieu of tumors.

Authors:  P M Gullino
Journal:  Prog Exp Tumor Res       Date:  1966

9.  Pharmacokinetics of methotrexate in leukemia cells: effect of dose and mode of injection.

Authors:  J M Weissbrod; R K Jain; F M Sirotnak
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

10.  The kinetics of methotrexate distribution in spontaneous canine lymphosarcoma.

Authors:  R J Lutz; R L Dedrick; J A Straw; M M Hart; P Klubes; D S Zaharko
Journal:  J Pharmacokinet Biopharm       Date:  1975-04
View more
  11 in total

1.  Pharmacokinetics of high-dose methotrexate in dogs. An experimental model with diffusion chambers.

Authors:  P Porpaczy; C P Schmidbauer; A Georgopoulos; A T Endler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

Review 3.  Transport of molecules across tumor vasculature.

Authors:  R K Jain
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats.

Authors:  S Dukic; T Heurtaux; M L Kaltenbach; G Hoizey; A Lallemand; B Gourdier; R Vistelle
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

Review 5.  1995 Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors.

Authors:  R K Jain
Journal:  Ann Biomed Eng       Date:  1996 Jul-Aug       Impact factor: 3.934

Review 6.  Vascular and interstitial barriers to delivery of therapeutic agents in tumors.

Authors:  R K Jain
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

7.  Delivery of molecular and cellular medicine to solid tumors.

Authors:  Rakesh K Jain
Journal:  Adv Drug Deliv Rev       Date:  2012-12-01       Impact factor: 15.470

Review 8.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Authors:  Rakesh K Jain
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

Review 9.  Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.

Authors:  Triantafyllos Stylianopoulos; Lance L Munn; Rakesh K Jain
Journal:  Trends Cancer       Date:  2018-03-13

Review 10.  Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid.

Authors:  Gianfranco Baronzio; Gurdev Parmar; Miriam Baronzio
Journal:  Front Oncol       Date:  2015-07-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.